Cerus/CERS

$1.67

-0.6%
-
1D1W1MYTD1YMAX

About Cerus

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Ticker

CERS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

William Greenman

Employees

288

Headquarters

Concord, United States

Cerus Metrics

BasicAdvanced
$313.62M
Market cap
-
P/E ratio
-$0.21
EPS
1.30
Beta
-
Dividend rate
$313.62M
1.29961
$3.08
$1.21
1.65M
2.139
1.549
113.573
151.559
-2.91%
-18.11%
-62.35%
-32.81%
1.679
5.956
6.109
-0.81%
13.95%
17.81%

What the Analysts think about Cerus

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
157.49% upside
High $6.00
Low $2.50
$1.67
Current price
$4.30
Average price target

Cerus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2.43% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$53.3M
12.92%
Net income
$-1.3M
-81.94%
Profit margin
-2.43%
-84.07%

Cerus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 58.33%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.09
-$0.07
-$0.04
-$0.01
-
Expected
-$0.08
-$0.06
-$0.05
-$0.02
-$0.05
Surprise
20%
25%
-23.81%
-58.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cerus stock?

Cerus (CERS) has a market cap of $313.62M as of April 17, 2024.

What is the P/E ratio for Cerus stock?

The price to earnings (P/E) ratio for Cerus (CERS) stock is 0 as of April 17, 2024.

Does Cerus stock pay dividends?

No, Cerus (CERS) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Cerus dividend payment date?

Cerus (CERS) stock does not pay dividends to its shareholders.

What is the beta indicator for Cerus?

Cerus (CERS) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cerus stock price target?

The target price for Cerus (CERS) stock is $4.3, which is 157.49% above the current price of $1.67. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cerus stock

Buy or sell Cerus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing